New advocacy resources to increase contraceptive access and choice with subcutaneous DMPA

PATH is pleased to launch the Advocacy Pack for Subcutaneous DMPA, a comprehensive suite of evidence-based tools that advocates can use to help increase access to a new type of injectable in their countries. 

Subcutaneous DMPA (DMPA-SC) is an innovative, easy-to-use injectable that is administered under the skin. It has the potential to dramatically increase contraceptive access by enabling community health workers to provide injections and even women to self-inject. DMPA-SC is currently being introduced or scaled in Family Planning 2020 (FP2020) countries as Pfizer’s branded product Sayana® Press.

The Advocacy Pack for Subcutaneous DMPA equips advocates with information, data, and tools to advance policy change and mobilize resources to support expanded access to this method, as part of a wide range of contraceptive options.

Advocacy pack highlights:

  • Available in English and French on the Reproductive Health Supplies Coalition website.
  • Consists of 15 tools to inform advocacy and communications planning and to support direct advocacy with decision-makers.
  • Based on the latest evidence on DMPA-SC.
  • Packaged as unbranded, customizable materials for country advocates and stakeholders.

Three ways to take action today: 

Thank you for your efforts to increase contraceptive access and choice for women and adolescent girls worldwide! Please send any questions or comments about these new resources to

The Advocacy Pack for Subcutaneous DMPA was developed by PATH in collaboration with international and national family planning organizations. Capital for Good, a grant recipient of the Bill & Melinda Gates Foundation, provided generous support for this project.
Cliquez pour en savoir plus

Partager cet article

Partager sur twitter
Partager sur facebook


Soyez informé des dernières actualités.

Inscrivez-vous !

Recevez toutes les actualités du PO directement dans votre boîte e-mail.